CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 4 Planned sale Chief Scientific Officer sold 8,000 shares at $16.33 ($130,640)
- 144 Insider Sale of Securities
- 4 Grant or award Chief Scientific Officer acquired 2,360 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Shareholder vote results
- 4 Option exercise Director acquired 18,450 shares (option exercise)
- SC 13G/A Stake Amended Statement of Ownership
- EFFECT Other Notice of Effectiveness
- 424B3 Offering Prospectus
- 8-K Event Regulation FD disclosure · Other events
- CORRESP Other Correspondence Between Filers and SEC Staff
- 8-K Event Regulation FD disclosure · Other events
- 4 Grant or award Director acquired 100,699 shares (grant or award)
- UPLOAD Other SEC-generated Letter
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- S-3 Offering Registration Statement
Page 9 of 24 · 471 filings